The study team will examine the effect of a ketogenic diet alone and ketogenic diet supplemented with oral ketones on how the body of individuals with type 2 diabetes respond to insulin, regulates insulin secretion, food intake and energetic pathways and influences body fat distribution.
Subjects will be randomized into three groups (1) standard, weight maintaining diet containing approximately 25-35% protein, 45-55% carbohydrate, 20-30% fat; (2) weight maintaining isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate, 70-80% fat; (3) weight maintaining isocaloric diet containing approximately 15-25% protein, 5-10% carbohydrate, 70-80% fat supplemented with the ketone ester of beta-hydroxy butyrate, 8 grams every 8 hours to further increase the plasma ketone concentration by \~3 mM. Subjects will be further randomized on the basis of: (i) HbA1c 7.0-8.5% and 8.5-10.5% to ensure similar baseline levels of glucose control and (ii) drug naïve versus drug-treated. At the time of screening, after a 10-12 hour overnight fast, indirect calorimetry will be performed with a ventilated hood system for 60 minutes to measure baseline energy expenditure. An initial weight maintenance energy requirement estimate as 1.5 times resting energy expenditure (obtained by indirect calorimetry) will be started. Diets will consist of a 10-day rotating menu using NutriAdmin for meal planning and Nutrition Maker for analysis of recipes Food will be prepared in the Cafeteria and or the Metabolic Kitchen at the Texas Diabetes Institute and certified by a dietician. Subjects will report to the diet kitchen at 8 AM on Monday through Saturday where they will eat their breakfast and pick up food for their lunch and dinner. On Saturday, participants also will be given food for their Sunday meals. Subjects will maintain a daily dietary log with all food consumed. On each visit subjects will be weighed; dietary log will be reviewed and the caloric content of the diet will be adjusted to maintain the body weight constant. Blood pressure will be measured in the reclining position x 2 separate days. Antidiabetic medications will not be changed during the study unless hypoglycemia (fasting plasma glucose \<70 mg/dl or symptoms) occurs. The study duration will be 10 days which should be sufficient to observe the effect of hyperketonemia on glucose/lipid metabolism and energy expenditure. If participant cannot come on the last days of his/her diet treatment, than we will extend this period up to 13 days and participant will be given diet for additional days till completion of the study visits.
Study Type
INTERVENTIONAL
Diet containing diet approximately 25-35% protein, 45-55% carbohydrate, 20- 30% fat
Isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate,70- 80% fat
A supplement of ketone ester of beta-hydroxy butyrate
University Health Systems-Texas Diabetes Institute
San Antonio, Texas, United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Fasting plasma glucose (FPG)
A change in FPG will be measured
Time frame: Baseline to 10 days
Hepatic Glucose production (HGP)
Change of hepatic glucose production will be measured using 3H-glucose infusion
Time frame: Baseline to 10 days
Whole Body Fat Oxidation
Change in whole body fat oxidation will be measured using indirect calorimetry
Time frame: Baseline to 10 days
Total Body Fat
Change in whole body fat
Time frame: Baseline to 10 days
Hepatic Fat Content
Change in hepatic fat content
Time frame: Baseline to 10 days
Plasma Insulin
Change in plasma insulin will be measured
Time frame: Baseline to 10 days
C-peptide
Change in C-peptide will be measured
Time frame: Baseline to 10 days
Free Fatty Acid (FFA)
Change in FFA will be measured
Time frame: Baseline to 10 days
Glycerol level
Change in Glycerol level will be measured
Time frame: Baseline to 10 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
35
Low density lipoproteins (LDL)
Change in LDL
Time frame: Baseline to 10 days
High density lipoproteins (HDL)
Change in HDL
Time frame: Baseline to 10 days
Triglycerides
Change in triglyceride levels
Time frame: Baseline to 10 days
Urine Microalbumin excretion
Change in urine microalbumin excretion
Time frame: Baseline to 10 days
Glycated hemoglobin test (HbA1c)
Change in HbA1c
Time frame: Baseline to 10 days
Fructosamine level
Change in fructosamine
Time frame: Baseline to 10 days